Project Grant R41DK142544
- This federal Project Grant award was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The $306,867 award to Dupage Medical Technology Inc. supports the development of a new drug to treat ischemia-reperfusion injury associated with kidney transplantation. The project aims to develop a therapy that can reduce inflammation and thrombosis without causing excessive...
- The Project Grant award AGT001 for Scleroderma Kidney, valued at $295,744, was awarded on September 15, 2025 by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports research by Angiotensin Therapeutics Inc., a biotechnology company in Evanston, Illinois, to evaluate the effectiveness of their bioengineered soluble Angiotensin-Converting-Enzyme 2 (AGT001) in...
- This $596,345 federal Project Grant was awarded on May 1, 2025 by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports research conducted by the Augusta University Research Institute, Inc. in Augusta, GA to investigate the molecular mechanisms underlying diabetic renal hypertrophy and its impact on acute kidney injury (AKI) susceptibility in diabetic...
- This federal Project Grant award, in the amount of $531,999.00, was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award is supporting research focused on understanding the role of alternative splicing in the proximal tubules of the kidney and its relationship to the progression of diabetic kidney disease. The research will investigate how diabetes...
- This $380,466 Cooperative Agreement, awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will fund a study titled "CARDIOVASCULAR AND RENAL PROTECTION WITH SGLT2 INHIBITION IN KIDNEY TRANSPLANT RECIPIENTS (RENAISSANCE)". The project aims to examine the potential benefits and risks of using sodium-glucose cotransporter-2 (SGLT2) inhibitor drugs in kidney...
- This $128,286 Project Grant award, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will support research into the mechanisms of renal lipotoxicity and its contribution to the development of chronic kidney disease (CKD). The principal investigator will investigate the protective role of the FAF2 gene knockout in mitigating palmitate-induced lipotoxicity in...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), through the Diabetes, Digestive, and Kidney Diseases Extramural Research Program (CFDA 93.847), awarded a $671,986 Project Grant to Rutgers, The State University of New Jersey, to conduct research aimed at strengthening the evidence-base for medication prescribing in older adults with chronic kidney disease (CKD). The key objectives of the 4-year project are to: 1) evaluate the effectiveness of renoprotective therapies...
- This federal Project Grant award of $3,010,432 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is funding research to develop mitoprotective therapies for the treatment of acute kidney injury (AKI). The key objectives of this research are to characterize a novel mitochondrial protein target, phospholipid scramblase 3 (PLSCR3), and evaluate pharmacological activators...
- This $243,750 Project Grant was awarded on September 5, 2025 by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports research to investigate the role of the protein DCLK1 in regulating the DNA damage response in proximal tubule cells, which are important mediators of chronic kidney disease (CKD). The research aims...
- This $2,833,514 Project Grant was awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant, titled "Renal Metabolism in AKI", will fund research to investigate changes in kidney metabolism in sepsis-associated acute kidney injury (AKI) and their impact on kidney tubule injury and recovery. The University of California, San Diego (UCSD) is the awardee...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $314,355 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Angiotensin Therapeutics Inc., a biotechnology company located in Evanston, Illinois. The funding supports research to develop a soluble form of the enzyme Angiotensin Converting Enzyme 2 (ACE2) as a potential treatment for delayed graft function (DGF), a form of acute kidney injury that affects up to 50% of deceased-donor kidney transplant recipients. The research aims to leverage ACE2's ability to reduce inflammation, fibrosis, and oxidative stress, which are key features of DGF, by engineering a more bioavailable ACE2 variant. The project commenced in September 2025 and is expected to be completed by August 2026.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $314.4k | 9/4/25 |